Back to results

CompletedPhase 2

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

NCT00265148

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

GSK Investigational Site

Litchfield Park, Arizona, United States

+14 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2004-05-18
Enrollment: 80 participants
Sponsor: GlaxoSmithKline
Purpose: treatment

Locations (15)

GSK Investigational SiteLitchfield Park, Arizona, United States
GSK Investigational SitePhoenix, Arizona, United States
GSK Investigational SiteScottsdale, Arizona, United States
GSK Investigational SiteSun City, Arizona, United States
GSK Investigational SiteTucson, Arizona, United States
GSK Investigational SiteLos Angeles, California, United States
GSK Investigational SiteBelmont, Massachusetts, United States
GSK Investigational SiteAnn Arbor, Michigan, United States
GSK Investigational SiteDurham, North Carolina, United States
GSK Investigational SiteMontreal, Quebec, Canada
GSK Investigational SiteMontreal, Quebec, Canada
GSK Investigational SiteLiverpool, United Kingdom
GSK Investigational SiteManchester, United Kingdom
GSK Investigational SiteSwindon, United Kingdom
GSK Investigational SiteWest End, Southampton, United Kingdom

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease — TrialFind